Similar articles

• Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.

  Mai HL, Cesbron A, Brouard S, Blanchol G, Cantarovich D, Dantal J, Hourmant M, Lino M, Meurette A, Gosselin M, Abbadie O, Soulillou JP, Giral M. Mai HL, et al. Clin Transpl. 2009:361-8. Clin Transpl. 2009. PMID: 20524299 No abstract available.
• Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.

  Al Meshari K. Al Meshari K. Clin Transpl. 2009:385-6. Clin Transpl. 2009. PMID: 20524302 No abstract available.
• Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.

  Cooper JE, Wiseman AC, Chan L. Cooper JE, et al. Clin Transpl. 2009:455-9. Clin Transpl. 2009. PMID: 20524314 No abstract available.
• Bortezomib: a new player in pre- and post-transplant desensitization?

  Lemy A, Toungouz M, Abramowicz D. Lemy A, et al. Nephrol Dial Transplant. 2010 Nov;25(11):3480-9. doi: 10.1093/ndt/gfq502. Epub 2010 Sep 8. Nephrol Dial Transplant. 2010. PMID: 20826741 Review.
• The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.

  Tzvetanov I, Spaggiari M, Joseph J, Jeon H, Thielke J, Oberholzer J, Benedetti E. Tzvetanov I, et al. Transplant Proc. 2012 Dec;44(10):2971-5. doi: 10.1016/j.transproceed.2012.02.037. Transplant Proc. 2012. PMID: 23195008 Review.